Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07395921

Resveratrol Effects on Inflammatory Biomarkers and Cardiometabolic Parameters.

Effects of Resveratrol Supplementation on Inflammatory Biomarkers and Cardiometabolic Parameters in Community-dwelling Adults. (RESINCA-trial)

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
75 (estimated)
Sponsor
Center for Research and Innovation Viña Concha y Toro · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

This study aims to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers and cardiometabolic parameters in community-dwelling adults

Detailed description

Three groups will be studied: control group (RES 120), experimental group 1 (RES 250) and experimental group 2 (RES 500). During 8 weeks the RES 120 group will received daily one grape pomace bars with 120 mg of total polyphenols contents (TPC), the RES 250 group will received daily one grape pomace bars enriched with resveratrol until reach 250 mg of TPC and the RES 500 group will received daily one grape pomace bars enriched with resveratrol until reach 500 mg of TPC. Outcomes will be assessed at baseline and after 8 weeks. At the end of the study, the groups that shows less o no effects will be invited to enjoy the bar showing to be more effective. Primary outcomes are: Total plasma antioxidant capacity (TAC), ultra-sensitivity CRP, IL-6, TNF-alfa, plasma malondialdehyde and AGEs. Secondary outcomes are: body weight, Body Mass Index (BMI), basal metabolic rate, fat mass, skeletal muscle mass, and waist-to-hip ratio. Handgrip strength, 30-second sit-to-stand test, and heart rate variability. Fasting insulin, fasting glucose, HOMA-IR. Lipid profile, liver profile, blood pressure. All procedures will be performed at the clinical simulation center of the Faculty of Medicine of the Catholic University of Maule. The sample size was estimated under the following criteria, using G\*Power software (version 3.1): Primary outcome: Total Plasma Antioxidant Capacity (TAC). Type of comparison: differences between parallel groups. Level of significance (α): 0.05 (bilateral). Stat (1 - β): 80%. Minimum expected difference (Δ): 0.25 TAC units. Standard deviation (σ): 0.30 TAC units. Balanced allocation between groups (1:1:1). The minimum sample size required is 23 participants per group, considering an estimated loss or dropout rate of 15-20%, the sample size was increased to 27- 30 participants per group.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTRES 120This grape pomace bar have 120 mg of total polyphenols contents
DIETARY_SUPPLEMENTRES 250This grape pomace bar is enriched with resveratrol until reach 250 mg of total polyphenols contents
DIETARY_SUPPLEMENTRES 500This grape pomace bar is enriched with resveratrol until reach 500 mg of total polyphenols contents

Timeline

Start date
2026-04-01
Primary completion
2026-08-31
Completion
2026-09-30
First posted
2026-02-09
Last updated
2026-02-09

Locations

1 site across 1 country: Chile

Source: ClinicalTrials.gov record NCT07395921. Inclusion in this directory is not an endorsement.